WNEB
Western New England Bancorp, Inc.
$13.32
-0.15%
$268.1M
No data for this timeframe.
Vol
Market Cap$268.1M
Cap SizeMicro Cap
Analyst ConsensusBuy (67%)
Inst. Holders7 funds
Inst. Value$29.3M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 2S
Insider Net $-$88.9K
SEC Reports3
Exchange Nasdaq·Sector Savings Institution, Federally Chartered·Inc. MA·CIK 0001157647·Prev Close $13.34
Recent Activity
May 20, 2026
Insider
Libiszewski Darlene M sold 3,680 shares
SVP, Chief Information Officer @ $13.42 ($49.4K)
May 14, 2026
SEC
Western New England Bancorp filed an 8-K to furnish its annual meeting presentation materials, which include financial r
8-K — Impact 3/10
May 6, 2026
Insider
Fitzgerald Gary G sold 353 shares
Director @ $14.30 ($5.0K)
May 6, 2026
Insider
Richter Steven G. sold 443 shares
Director @ $14.30 ($6.3K)
Apr 28, 2026
SEC
WNEB reported Q1 2026 diluted EPS of $0.24, beating consensus of $0.21 by 14.3%, and net interest income rose 21.2% YoY
8-K — Impact 5/10
Apr 3, 2026
SEC
Western New England Bancorp, Inc. (WNEB) has issued definitive proxy materials for its 2026 Annual Meeting of Shareholde
DEFA14A — Impact 3/10
Inst.
MORGAN STANLEY — TRIM
49,442 shares ($624.0K)
Inst.
WELLS FARGO & COMPANY/MN — ADD
24,282 shares ($306.4K)
Price Targets
$15.17
+11.8% upside
Buy
Current $13.57
Low $14.50
Median $15.00
High $16.00
3 analysts
$14.50
$16.00
Analyst Ratings
2Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | Seaport Global | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.24 ▲ +2.1% | $0.23 — $0.25 | 4% YoY | 3 |
| Next Q | $0.25 ▲ +1.3% | $0.25 — $0.26 | 58% YoY | 3 |
| Current FY | $0.99 ▲ +3.3% | $0.96 — $1.03 | 32% YoY | 3 |
| Next FY | $1.11 ▲ +3.3% | $1.00 — $1.23 | 13% YoY | 3 |
Latest Reports
NEUTRAL
8-K
3/10
Western New England Bancorp filed an 8-K to furnish its annual meeting presentation materials, which include financial r
May 14, 2026
NEUTRAL
8-K
5/10
WNEB reported Q1 2026 diluted EPS of $0.24, beating consensus of $0.21 by 14.3%, and net interest income rose 21.2% YoY
Apr 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $13.7M | — |
| RENAISSANCE TECHNOLOGIES LLC | $13.2M | — |
| BANK OF AMERICA CORP | $749.4K | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $711.9K | DOUBLED |
| MORGAN STANLEY | $624.0K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Libiszewski Darlene | SELL | $49.4K |
| May 6, 2026 | Fitzgerald Gary | A | $5.0K |
| May 6, 2026 | Richter Steven | A | $6.3K |
| May 6, 2026 | McMahon Lisa | A | $3.7K |
| May 6, 2026 | PICKNELLY PAUL | A | $7.7K |
7 institutional holders with $29.3M total value (2,321,349 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,081,836 | $13.7M | 46.6% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,048,362 | $13.2M | 45.2% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 59,384 | $749.4K | 2.6% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 56,410 | $711.9K | 2.4% | DOUBLED +445.1% |
| 5 | MORGAN STANLEY | 49,442 | $624.0K | 2.1% | TRIM -48.2% |
| 6 | WELLS FARGO & COMPANY/MN | 24,282 | $306.4K | 1.0% | ADD +65.9% |
| 7 | FMR LLC | 1,633 | $20.6K | 0.1% | DOUBLED +118.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 95,533 | 49,442 | -48.2% | $624.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 14,634 | 24,282 | +65.9% | $306.4K | 2025-Q4 |
| FMR LLC | DOUBLED | 749 | 1,633 | +118.0% | $20.6K | 2025-Q4 |
| FMR LLC | TRIM | 1,314 | 749 | -43.0% | $9.0K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 40,078 | 99,310 | +147.8% | $916.6K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 10,349 | 56,410 | +445.1% | $520.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1 | 11,799 | +1179800.0% | $108.9K | 2025-Q2 |
| UBS Group AG | ADD | 21,434 | 33,901 | +58.2% | $315.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 15,341 | 24,523 | +59.9% | $228.1K | 2025-Q1 |
| UBS Group AG | ADD | 16,044 | 21,434 | +33.6% | $197.2K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 15,341 | — | $141.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 10,349 | — | $88.0K | 2024-Q3 |
17 unique insiders with 2 transactions. Net insider value: -$88.9K ($0.00 bought, $88.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Libiszewski Darlene M | SVP, Chief Information Officer | SELL | 3,680 | $13.42 | $49.4K |
| May 6, 2026 | Fitzgerald Gary G | Director | A | 353 | $14.30 | $5.0K |
| May 6, 2026 | Richter Steven G. | Director | A | 443 | $14.30 | $6.3K |
| May 6, 2026 | McMahon Lisa G | Director | A | 259 | $14.30 | $3.7K |
| May 6, 2026 | PICKNELLY PAUL C | Director | A | 537 | $14.30 | $7.7K |
| May 6, 2026 | MASSE WILLIAM D | Director | A | 323 | $14.30 | $4.6K |
| May 6, 2026 | Damon Donna J. | Director | A | 296 | $14.30 | $4.2K |
| Mar 6, 2026 | Fitzgerald Gary G | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | McMahon Lisa G | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | MASSE WILLIAM D | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | HAGAN JAMES C | President and CEO | A | 11,735 | $0.00 | $0.00 |
| Mar 6, 2026 | Sajdak Guida R | EVP, CFO & Treasurer | A | 3,793 | $0.00 | $0.00 |
| Mar 6, 2026 | Smith Philip R | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | O'Connor Kevin C | EVP & Chief Operating Officer | A | 3,427 | $0.00 | $0.00 |
| Mar 6, 2026 | Richter Steven G. | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | Benoit Laura | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | Bonini John E | SVP, General Counsel | A | 2,792 | $0.00 | $0.00 |
| Mar 6, 2026 | Damon Donna J. | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | Libiszewski Darlene M | SVP, Chief Information Officer | A | 2,690 | $0.00 | $0.00 |
| Mar 6, 2026 | Miles Allen J III | EVP & Chief Lending Officer | A | 4,246 | $0.00 | $0.00 |
| Mar 6, 2026 | Goncalves Filipe B | SVP & CCO | A | 3,041 | $0.00 | $0.00 |
| Mar 6, 2026 | Phillips Christine | SVP & Chief HR Officer | A | 2,684 | $0.00 | $0.00 |
| Mar 6, 2026 | PICKNELLY PAUL C | Director | A | 1,603 | $0.00 | $0.00 |
| Mar 6, 2026 | SAGAN LEO R JR | SVP & Chief Risk Officer | A | 2,840 | $0.00 | $0.00 |
| Feb 27, 2026 | Smith Philip R | Director | SELL | 3,000 | $13.17 | $39.5K |
| Feb 4, 2026 | Benoit Laura | Director | A | 29 | $14.23 | $412.74 |
| Feb 4, 2026 | MASSE WILLIAM D | Director | A | 305 | $14.23 | $4.3K |
| Feb 4, 2026 | PICKNELLY PAUL C | Director | A | 514 | $14.23 | $7.3K |
| Feb 4, 2026 | Fitzgerald Gary G | Director | A | 325 | $14.23 | $4.6K |
| Feb 4, 2026 | Damon Donna J. | Director | A | 320 | $14.23 | $4.6K |
| Feb 4, 2026 | McMahon Lisa G | Director | A | 267 | $14.23 | $3.8K |
| Feb 4, 2026 | Richter Steven G. | Director | A | 467 | $14.23 | $6.6K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
3/10
Western New England Bancorp filed an 8-K to furnish its annual meeting presentation materials, which
May 14, 2026
NEUTRAL
8-K
5/10
WNEB reported Q1 2026 diluted EPS of $0.24, beating consensus of $0.21 by 14.3%, and net interest in
Apr 28, 2026
NEUTRAL
DEFA14A
3/10
Western New England Bancorp, Inc. (WNEB) has issued definitive proxy materials for its 2026 Annual M
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (67% buy). Based on 9 analysts: 2 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.17 mean target
+11.8% upside
Buy (3.00)
$14.50 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $13.57 |
| Target Low | $14.50 |
| Target Mean | $15.17 |
| Target Median | $15.00 |
| Target High | $16.00 |
| # Analysts | 3 |
| Recommendation | Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.24 | $0.23 | $0.25 | 4.3% | +2.1% | — | $0.0B | 10.7% | 3 |
| Next Q 2026-09-30 |
$0.25 | $0.25 | $0.26 | 58.3% | +1.3% | 0↑ 1↓ | $0.0B | 10.6% | 3 |
| Current FY 2026-12-31 |
$0.99 | $0.96 | $1.03 | 31.6% | +3.3% | 1↑ 0↓ | $0.1B | 12.4% | 3 |
| Next FY 2027-12-31 |
$1.11 | $1.00 | $1.23 | 12.5% | +3.3% | 1↑ 0↓ | $0.1B | 7.5% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.240 | |
| 7d ago | $0.237 | +0.003 |
| 30d ago | $0.235 | +0.005 |
| 60d ago | $0.230 | +0.010 |
| 90d ago | $0.230 | +0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | Seaport Global | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| May 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Apr 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 20, 2026
earnings_calendar
WNEB Q1 2026 Earnings Scheduled — 2026-04-20
Mar 23, 2026
clinical_trial_readout
T-90d Trial Readout: BL-B01D1 (Phase 3)
Trial: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative
Mar 17, 2026
Clinical Trial
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Phase Phase 2 — COMPLETED
Mar 9, 2026
Clinical Trial
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Mar 9, 2026
clinical_trial_readout
T-90d Trial Readout: RMC-6236 (Phase 3)
Trial: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor: Revolu
Mar 9, 2026
clinical_trial_readout
T-90d Trial Readout: BL-B01D1 (Phase 3)
Trial: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative
Mar 3, 2026
clinical_trial_readout
T-90d Trial Readout: Domvanalimab (Phase 3)
Trial: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tr
Mar 2, 2026
Clinical Trial
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
Phase Phase 2 — COMPLETED
Jul 17, 2017
FDA
TRANEXAMIC ACID
Aug 20, 2015
FDA
DEXMEDETOMIDINE HYDROCHLORIDE